
May 31 (Reuters) - Xilio Therapeutics Inc XLO.O:
XILIO THERAPEUTICS ANNOUNCES UPDATED PHASE 2 DATA FOR VILASTOBART, A TUMOR-ACTIVATED ANTI-CTLA-4, IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH METASTATIC MICROSATELLITE STABLE COLORECTAL CANCER
XILIO THERAPEUTICS INC - 26% RESPONSE RATE IN METASTATIC MSS CRC WITHOUT LIVER METASTASES
XILIO THERAPEUTICS INC - VILASTOBART AND ATEZOLIZUMAB SHOW WELL-TOLERATED SAFETY PROFILE